Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EARNINGS ROUND-UP: ILMN, SYK, TMO, VAR

This article was originally published in Clinica

Executive Summary

Genome sequencing specialist Illumina’s share price jumped after it posted 27% sales growth during its first fiscal quarter. Its stock closed up 5% at $147.98 on 22 April, the day it reported the results, and climbed another 4% to close at $153.69 the following day. Its share price hit an all-time high of $179.65 in February, making a mockery of Roche’s $51 per share offer in 2012. Illumina has increased its guidance for full-year 2014 and is now predicting 21-23% revenue growth (from 15-17% previously) and non-GAAP earnings of $2.10-2.15 per diluted share (from $2.00-2.06).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT101529

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel